These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9129067)

  • 1. In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors.
    Lazdins JK; Mestan J; Goutte G; Walker MR; Bold G; Capraro HG; Klimkait T
    J Infect Dis; 1997 May; 175(5):1063-70. PubMed ID: 9129067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors.
    Zhang XQ; Schooley RT; Gerber JG
    J Infect Dis; 1999 Dec; 180(6):1833-7. PubMed ID: 10558938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
    Schütt M; Zhou J; Meier M; Klein HH
    J Endocrinol; 2004 Dec; 183(3):445-54. PubMed ID: 15590971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.
    Perno CF; Newcomb FM; Davis DA; Aquaro S; Humphrey RW; Caliò R; Yarchoan R
    J Infect Dis; 1998 Aug; 178(2):413-22. PubMed ID: 9697721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
    Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
    Hazen R; Harvey R; Ferris R; Craig C; Yates P; Griffin P; Miller J; Kaldor I; Ray J; Samano V; Furfine E; Spaltenstein A; Hale M; Tung R; St Clair M; Hanlon M; Boone L
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3147-54. PubMed ID: 17620375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors.
    Gruber A; Berlit J; Speth C; Lass-Flörl C; Kofler G; Nagl M; Borg-von Zepelin M; Dierich MP; Würzner R
    Immunobiology; 1999 Sep; 201(1):133-44. PubMed ID: 10532286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro.
    Merrill DP; Manion DJ; Chou TC; Hirsch MS
    J Infect Dis; 1997 Jul; 176(1):265-8. PubMed ID: 9207379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to human immunodeficiency virus type 1 protease inhibitors.
    Boden D; Markowitz M
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2775-83. PubMed ID: 9797203
    [No Abstract]   [Full Text] [Related]  

  • 11. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors.
    Descamps D; Apetrei C; Collin G; Damond F; Simon F; Brun-Vézinet F
    AIDS; 1998 Jun; 12(9):1109-11. PubMed ID: 9662212
    [No Abstract]   [Full Text] [Related]  

  • 12. Susceptibilities of simian immunodeficiency virus to protease inhibitors.
    Giuffre AC; Higgins J; Buckheit RW; North TW
    Antimicrob Agents Chemother; 2003 May; 47(5):1756-9. PubMed ID: 12709355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 protease inhibitors. A review for clinicians.
    Deeks SG; Smith M; Holodniy M; Kahn JO
    JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.
    Partaledis JA; Yamaguchi K; Tisdale M; Blair EE; Falcione C; Maschera B; Myers RE; Pazhanisamy S; Futer O; Cullinan AB
    J Virol; 1995 Sep; 69(9):5228-35. PubMed ID: 7636964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
    Mo H; Parkin N; Stewart KD; Lu L; Dekhtyar T; Kempf DJ; Molla A
    Antimicrob Agents Chemother; 2007 Feb; 51(2):732-5. PubMed ID: 17101675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Resistance to protease inhibitors].
    Clotet B; Martínez-Picado J; Arrizabalaga J; Ruiz L
    Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):34-41. PubMed ID: 11428058
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.
    Jones K; Hoggard PG; Khoo S; Maher B; Back DJ
    Br J Clin Pharmacol; 2001 Jan; 51(1):99-102. PubMed ID: 11167671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profile of CGP 61755: a novel and potent HIV-1 protease inhibitor that shows enhanced anti-HIV activity when combined with other antiretroviral agents in vitro.
    Lazdins JK; Bold G; Capraro HG; Cozens R; Fässler A; Flesch G; Klimkait T; Lang M; Mestan J; Poncioni B; Rösel J; Stover D; Tintelnot-Blomley M; Walker MR; Woods-Cook K
    Schweiz Med Wochenschr; 1996 Oct; 126(43):1849-51. PubMed ID: 8916294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
    Leonis G; Steinbrecher T; Papadopoulos MG
    J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line.
    Dupuis ML; Tombesi M; Sabatini M; Cianfriglia M
    Chemotherapy; 2003 May; 49(1-2):8-16. PubMed ID: 12714803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.